Recent Progress of RGD Modified Liposomes As Multistage Rocket Against Cancer

Overview

Journal Front Pharmacol

Date 2022 Feb 11

PMID 35145405

Authors

Afsana Sheikh

Nabil A Alhakamy

Shadab Md

Prashant Kesharwani

Affiliations

Soon will be listed here.

Abstract

Cancer is a life-threatening disease, contributing approximately 9.4 million deaths worldwide. To address this challenge, scientific researchers have investigated molecules that could act as speed-breakers for cancer. As an abiotic drug delivery system, liposomes can hold both hydrophilic and lipophilic drugs, which promote a controlled release, accumulate in the tumor microenvironment, and achieve elongated half-life with an enhanced safety profile. To further improve the safety and impair the off-target effect, the surface of liposomes could be modified in a way that is easily identified by cancer cells, promotes uptake, and facilitates angiogenesis. Integrins are overexpressed on cancer cells, which upon activation promote downstream cell signaling and eventually activate specific pathways, promoting cell growth, proliferation, and migration. RGD peptides are easily recognized by integrin over expressed cells. Just like a multistage rocket, ligand anchored liposomes can be selectively recognized by target cells, accumulate at the specific site, and finally, release the drug in a specific and desired way. This review highlights the role of integrin in cancer development, so gain more insights into the phenomenon of tumor initiation and survival. Since RGD is recognized by the integrin family, the fate of RGD has been demonstrated after its binding with the acceptor's family. The role of RGD based liposomes in targeting various cancer cells is also highlighted in the paper.

Citing Articles

The Use of Plant Viral Nanoparticles in Cancer Biotherapy-A Review.

Komane M, Kayoka-Kabongo P, Rutkowska D Viruses. 2025; 17(2).

PMID: 40006973 PMC: 11860677. DOI: 10.3390/v17020218.

Double Peptide-Functionalized Carboxymethyl Chitosan-Coated Liposomes Loaded with Dexamethasone as a Potential Strategy for Active Targeting Drug Delivery.

Iftode L, Cadinoiu A, Rata D, Atanase L, Vochita G, Radulescu L Int J Mol Sci. 2025; 26(3).

PMID: 39940692 PMC: 11816442. DOI: 10.3390/ijms26030922.

Improving dexamethasone drug loading and efficacy in treating rheumatoid arthritis via liposome: Focusing on inflammation and molecular mechanisms.

Zamanian M, Zafari H, Osminina M, Skakodub A, Aboqader Al-Aouadi R, Golmohammadi M Animal Model Exp Med. 2024; 8(1):5-19.

PMID: 39627850 PMC: 11798740. DOI: 10.1002/ame2.12518.

Metal Peroxide Nanoparticles for Modulating the Tumor Microenvironment: Current Status and Recent Prospects.

Rajaram J, Kuthati Y Cancers (Basel). 2024; 16(21).

PMID: 39518022 PMC: 11545372. DOI: 10.3390/cancers16213581.

Increased Cellular Uptake of ApoE3- or c(RGD)-Modified Liposomes for Glioblastoma Therapy Depending on the Target Cells.

Lubitz L, Haffner M, Rieger H, Leneweit G Pharmaceutics. 2024; 16(9).

PMID: 39339149 PMC: 11434700. DOI: 10.3390/pharmaceutics16091112.

References

Onodera Y, Nam J, Sabe H . Intracellular trafficking of integrins in cancer cells. Pharmacol Ther. 2013; 140(1):1-9. DOI: 10.1016/j.pharmthera.2013.05.007. View

Ruan S, Zhou Y, Jiang X, Gao H . Rethinking CRITID Procedure of Brain Targeting Drug Delivery: Circulation, Blood Brain Barrier Recognition, Intracellular Transport, Diseased Cell Targeting, Internalization, and Drug Release. Adv Sci (Weinh). 2021; 8(9):2004025. PMC: 8097396. DOI: 10.1002/advs.202004025. View

Kesharwani P, Gothwal A, Iyer A, Jain K, Chourasia M, Gupta U . Dendrimer nanohybrid carrier systems: an expanding horizon for targeted drug and gene delivery. Drug Discov Today. 2017; 23(2):300-314. DOI: 10.1016/j.drudis.2017.06.009. View

Murphy C, Dickler M . Endocrine resistance in hormone-responsive breast cancer: mechanisms and therapeutic strategies. Endocr Relat Cancer. 2016; 23(8):R337-52. DOI: 10.1530/ERC-16-0121. View

Bandak S, Goren D, Horowitz A, Tzemach D, Gabizon A . Pharmacological studies of cisplatin encapsulated in long-circulating liposomes in mouse tumor models. Anticancer Drugs. 2000; 10(10):911-20. DOI: 10.1097/00001813-199911000-00007. View

Li Y, Xiao Y, Lin H, Reichel D, Bae Y, Lee E . In vivo β-catenin attenuation by the integrin α5-targeting nano-delivery strategy suppresses triple negative breast cancer stemness and metastasis. Biomaterials. 2018; 188:160-172. DOI: 10.1016/j.biomaterials.2018.10.019. View

Ruoslahti E . RGD and other recognition sequences for integrins. Annu Rev Cell Dev Biol. 1996; 12:697-715. DOI: 10.1146/annurev.cellbio.12.1.697. View

Ahmad K, Lee E, Shaikh S, Kumar A, Rao K, Park S . Targeting integrins for cancer management using nanotherapeutic approaches: Recent advances and challenges. Semin Cancer Biol. 2019; 69:325-336. DOI: 10.1016/j.semcancer.2019.08.030. View

He C, Hu Y, Yin L, Tang C, Yin C . Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles. Biomaterials. 2010; 31(13):3657-66. DOI: 10.1016/j.biomaterials.2010.01.065. View

10.

Yeo W, Mok T, Zee B, Leung T, Lai P, Lau W . A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst. 2005; 97(20):1532-8. DOI: 10.1093/jnci/dji315. View

11.

Zhang L, Zhu S, Qian L, Pei Y, Qiu Y, Jiang Y . RGD-modified PEG-PAMAM-DOX conjugates: in vitro and in vivo studies for glioma. Eur J Pharm Biopharm. 2011; 79(2):232-40. DOI: 10.1016/j.ejpb.2011.03.025. View

12.

Cooper J, Giancotti F . Integrin Signaling in Cancer: Mechanotransduction, Stemness, Epithelial Plasticity, and Therapeutic Resistance. Cancer Cell. 2019; 35(3):347-367. PMC: 6684107. DOI: 10.1016/j.ccell.2019.01.007. View

13.

Afsana , Jain V, Haider N, Jain K . 3D Printing in Personalized Drug Delivery. Curr Pharm Des. 2019; 24(42):5062-5071. DOI: 10.2174/1381612825666190215122208. View

14.

Shi J, Wang L, Kim Y, Zhai S, Liu Z, Chen X . Improving tumor uptake and excretion kinetics of 99mTc-labeled cyclic arginine-glycine-aspartic (RGD) dimers with triglycine linkers. J Med Chem. 2008; 51(24):7980-90. PMC: 2626178. DOI: 10.1021/jm801134k. View

15.

Zuo T, Guan Y, Chang M, Zhang F, Lu S, Wei T . RGD(Arg-Gly-Asp) internalized docetaxel-loaded pH sensitive liposomes: Preparation, characterization and antitumor efficacy in vivo and in vitro. Colloids Surf B Biointerfaces. 2016; 147:90-99. DOI: 10.1016/j.colsurfb.2016.07.056. View

16.

Kesharwani P, Tekade R, Jain N . Generation dependent cancer targeting potential of poly(propyleneimine) dendrimer. Biomaterials. 2014; 35(21):5539-48. DOI: 10.1016/j.biomaterials.2014.03.064. View

17.

Keikha M, Esfahani B . The Relationship between Tuberculosis and Lung Cancer. Adv Biomed Res. 2018; 7:58. PMC: 5887688. DOI: 10.4103/abr.abr_182_17. View

18.

Burroughs A, Hochhauser D, Meyer T . Systemic treatment and liver transplantation for hepatocellular carcinoma: two ends of the therapeutic spectrum. Lancet Oncol. 2004; 5(7):409-18. DOI: 10.1016/S1470-2045(04)01508-6. View

19.

Alphandery E, Grand-Dewyse P, Lefevre R, Mandawala C, Durand-Dubief M . Cancer therapy using nanoformulated substances: scientific, regulatory and financial aspects. Expert Rev Anticancer Ther. 2015; 15(10):1233-55. DOI: 10.1586/14737140.2015.1086647. View

20.

Li J, Chai Z, Lu J, Xie C, Ran D, Wang S . ɑβ-targeted liposomal drug delivery system with attenuated immunogenicity enabled by linear pentapeptide for glioma therapy. J Control Release. 2020; 322:542-554. DOI: 10.1016/j.jconrel.2020.04.009. View